SMO and ovarian carcinoma: To validate this interpretation, we tested the ability of two different Hedgehog inhibitors, namely cyclopamine (CP), that antagonizes Smoothened (Smo) activity, and GANT61, that specifically targets GLI1-mediated transcription, to inhibit LPA-induced ovarian cancer cell migration (SKOV3 cells were chosen as representative).